Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 13/20 | 0.64 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19611476 | 0.94 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19611479 | 0.94 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19611478 | 0.94 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| Trifluoroacetic Acid SCHEMBL19611495 | 0.88 | FOLH1 (0.57) | FOLH1RIMKLANAALAD2 | |
| Trifluoroacetic Acid SCHEMBL19611496 | 0.88 | FOLH1 (0.57) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL21162263 | 0.86 | FOLH1 (0.66) | FOLH1RIMKLANAALAD2SLC6A5 | |
| SCHEMBL19633812 | 0.80 | FOLH1 (0.66) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL27611756 | 0.79 | FOLH1 (0.54) | FOLH1SLC6A5CPB2 | |
| SCHEMBL15739333 | 0.79 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL2450650 | 0.79 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078166-B2 | Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190225589-A1 | TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND REVERSED CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-07-25 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170081298-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-03-23 | — | — | US | disclosed |
| WO-2015171792-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081298-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | PSMA6, PSMA1, UTS2R | FOLH1 32/4885RIMKLA 1680/4885NAALAD2 720/4885 |
| US-11078166-B2 | Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof | PAICS, FOLH1, UTS2R | FOLH1 2/4885RIMKLA 1026/4885NAALAD2 213/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | FOLH1 94/4885RIMKLA 3213/4885NAALAD2 1066/4885 |
| US-20190225589-A1 | TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND REVERSED CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF | PAICS, FOLH1, UTS2R | FOLH1 2/4885RIMKLA 1026/4885NAALAD2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.